Study | Subgroups by MP status | Exposure categories (n) | Oldest/youngest age category | RR (95% CI) for oldest vs. youngest age category | |
---|---|---|---|---|---|
ER+PR+ | ER-PR- | ||||
Cohort study | |||||
[9] | Post-MP | 2 | ≥30/<30 | 1.76 (1.21–2.56) | 1.71 (0.76–3.85) |
Population-based case-control studies | |||||
[11] | All women | 2 | >25/≤ 25 | 1.3 (0.9–1.8) | 0.8 (0.5–1.3) |
Pre-MP | 2 | >25/≤ 25 | 1.0 (0.6–1.7) | 0.9 (0.5–1.5) | |
Post-MP | 2 | >25/≤ 25 | 1.6 (1.0–2.7) | 0.9 (0.4–1.7) | |
[12] | Young | 2 | >24.3/≤ 24.3 | 1.21 (0.94–1.57) | 1.03 (0.75–1.41) |
[13] | All women | 3 | ≥28/<24 | 1.43 (1.06–1.92) | 1.19 (0.78–1.81) |
Pre-MP | 3 | ≥28/<24 | 1.08 (0.73–1.60) | 1.00 (0.60–1.65) | |
Post-MP | 3 | ≥28/<24 | 1.64 (1.28–2.10) | 1.30 (0.89–1.89) | |
[14] | Young | 2 | ≥25/<25 | 1.7 (1.1–2.5) | 0.9 (0.6–1.4) |
[7] | All women | 4 | ≥30/<20 | 1.22 (0.97–1.54) | 0.91 (0.68–1.22) |
[8] | Young | 4 | ≥32/<22 | 1.23 (0.72–2.10) | 0.56 (0.30–1.07) |
Summary RRs for population-based case-control studies | 1.31 (1.07–1.60) | 0.94 (0.76–1.15) | |||
Hospital-based case-control studies | |||||
[15] | All women | Per 5 years↑ | 5 years' increase | 1.19 (0.93–1.51) | 1.19 (0.91–1.55) |
[16] | All women | 2 | ≥30/<30 | 0.5 (0.2–1.2) | 1.0 (0.5–1.9) |
Summary RRs for hospital-based case-control studies | 1.10 (0.78–1.55) | 1.17 (0.83–1.65) | |||
Summary RRs by MP status | Pre-MP/Young | 1.24 (0.96–1.62) | 0.92 (0.71–1.20) | ||
Post-MP | 1.65 (1.15–2.38) | 1.28 (0.89–1.84) | |||
Summary RRs for all studies | 1.27 (1.07–1.50) | 1.01 (0.85–1.20) | |||
P for homogeneity between ER+PR+ and ER-PR- cancer | p = 0.010 |